title: Colloidal bismuth subcitrate in peptic ulcer disease.
abstract: The pharmacological mechanism of ulcer coating and cytoprotection associated with colloidal bismuth have important therapeutic implications for the management of peptic ulcer disease. While the short-term healing rate is similar to that obtained by the H2 antagonists, the relapse rate appears lower.
mesh_terms: D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001729:Bismuth / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004381:Duodenal Ulcer / Q000188:drug therapy*; D006801:Humans; D009942:Organometallic Compounds; D010437:Peptic Ulcer / Q000188:drug therapy*; D013276:Stomach Ulcer / Q000188:drug therapy*
chemical_list: D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; C002791:bismuth tripotassium dicitrate; D001729:Bismuth